01.12.2020 | editorial
Treating head and neck cancer—A multidisciplinary effort
Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2020
Einloggen, um Zugang zu erhaltenExcerpt
Head and neck (HNC) is the tenth most common cancer worldwide with over 650,000 new cases per year [ 1‐ 3]. The major risk factors for development of squamous cell HNC comprise alcohol and tobacco consumption [ 4]. During the last few decades human papilloma virus (HPV) infection has been identified to contribute to the development of oropharyngeal HNC in a younger subgroup of patients [ 5]. This population shows a more favorable prognosis compared to HPV-negative disease [ 5]. Standard treatment options for HNC independent of HPV status include surgery, standard radiation, chemo- or bioradiation and chemotherapy. …Anzeige